Lung Cancer News

Most patients with non-small cell lung cancer had an adequate antibody response to COVID-19 vaccines, research published in Journal of Clinical Oncology showed.

CHICAGO — Comprehensive genomic profiling, or GCP, among patients with resected early-stage non-small cell lung cancer demonstrated a potential cost-benefit according to data presented at ASCO Annual Meeting.

The development of targeted cancer therapies has led to improved clinical outcomes for many patients. However, monotherapies against a single target can result in treatment resistance.

CHICAGO — Including liquid biopsy in the initial diagnostic workup of patients with stage IV nonsquamous non-small cell lung cancer resulted in a quicker initiation of first-line therapy and a higher detection rate of actionable mutations.

Patients with thoracic cancer who were Black, had Medicaid or resided in areas with high rates of cancer mortality had increased odds of unsuccessful telemedicine visits, according to study results published in JAMA Network Open.

CHICAGO — For patients with advanced non-small cell lung cancer who showed an inadequate response to front-line immunotherapy checkpoint inhibitors and chemotherapy, the addition of CAN-2409 was well-tolerated.

Alex A. Adjei, MD, PhD, has been appointed chair of Cleveland Clinic Taussig Cancer Institute.

CHICAGO — Among patients with stage III non-small cell lung cancer who completed chemoradiation, over one-quarter did not receive consolidation immune checkpoint inhibitors, according to findings presented at ASCO Annual Meeting.

The FDA granted orphan drug designation to several therapies in development for oncology indications.

Various sociodemographic and socioeconomic factors, including race/ethnicity and insurance status, correlated with receipt of immunotherapy among patients with melanoma and kidney and lung cancers.